MRNA · 10-Q · 2026Q2 · Full report

Litigation Settlement Exposure

Moderna, Inc. · 2026-07-31 · Importance 71 · Surprise 60 · Matches filing data

Moderna recorded $884 million of third-party royalty and amortization expense during the six months ended June 30, 2026 related to the Arbutus and Genevant litigation settlement. The company accrued a $950 million settlement obligation as of June 30, 2026 and paid that amount in July 2026. Moderna appealed the District Court’s decision under 28 U.S.C. § 1498 to the Federal Circuit and could owe an additional payment of up to $1.3 billion, although no accrual was recorded because a loss was not considered probable. The company also faces patent litigation involving Pfizer and BioNTech, GSK, Northwestern University, Bayer/Monsanto, mNG Bio, CureVac, BioNTech and Sanofi entities across U.S. and European jurisdictions, plus shareholder litigation concerning its RSV vaccine.

Key facts

• Moderna, Inc. could be required to make an additional payment of up to $1.3 billion depending on the outcome of the appeal related to 28 U.S.C. § 1498. source
• Moderna, Inc. accrued a $950 million litigation settlement obligation as of June 30, 2026 which was paid in July 2026. source
• The maximum potential amount of future payments Moderna, Inc. could be required to make under its indemnification provisions is unlimited. source
• Moderna, Inc. has brought patent-infringement actions against Pfizer Inc. and BioNTech SE and related entities in the U.S., Germany, the Netherlands, the UK, Ireland and Belgium concerning its mRNA platform technology and disease-specific vaccine designs. source
• GlaxoSmithKline Biologicals SA (GSK) has filed two complaints against Moderna, Inc. in the U.S. District Court for the District of Delaware asserting certain patents owned by GSK. source
• GSK has filed two patent-infringement lawsuits against Moderna, Inc. in the UPC concerning liposomes and modified liposomes for RNA delivery. source
• Northwestern University has filed a complaint against Moderna, Inc. in the U.S. District Court for the District of Delaware asserting U.S. patents concerning lipid nanoparticle technology. source
• Bayer CropSciences LLC, Monsanto Company, and Monsanto Technology, LLC have filed a complaint against Moderna, Inc. in the U.S. District Court for the District of Delaware asserting a U.S. patent directed to methods of modifying gene sequences. source

Impact estimates